clinical trial · NCT07360314
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
EMD Serono Research & Development Institute, Inc.·phase1·recruiting·n = 138
Advanced Solid TumorsM7437M7437
brief summary
The purpose of this first-in-human (FIH) study is to evaluate the safety, tolerability, Pharmacokinetics (PK), and preliminary clinical activity of M7437 in participants with locally advanced or metastatic solid tumors with known Ly6E expression, including non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), epithelial ovarian carcinoma (EOC), squamous cell carcinoma of the head and neck (SCCHN), pancreatic ductal adenocarcinoma (PDAC), and gastric cancer (GC).
started
Feb 13, 2026
primary completion
Sep 20, 2028
completion
Mar 28, 2029
last updated
Jun 11, 2026
official title
A Phase 1, 2-Part, Multicenter, Open-Label, First-in-Human Study of the Anti-Ly6E Exatecan Antibody-Drug Conjugate M7437 in Participants With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol